TMDX241220C45000
- 97.50
- 0.000.00%
TransMedics Newsroom
Oppenheimer Maintains Outperform on TransMedics Gr, Maintains $125 Price Target
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $104 to $120
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics, Inc. (APGE) and TransMedics Group (TMDX)
TransMedics Gr Analyst Ratings
TransMedics' Positive Trajectory: Buy Rating Reinforced by Growth in Heart and Lung Transplants
Needham Downgrades TransMedics(TMDX.US) to Hold Rating
TransMedics Group Price Target Maintained With a $109.00/Share by Needham
Oppenheimer Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $125
TransMedics Group (TMDX) Gets a Buy From Oppenheimer
TransMedics Group Is Maintained at Buy by Canaccord Genuity
CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $104
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $110
TransMedics Gr Analyst Ratings
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $120
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $180
Morgan Stanley Maintains TransMedics(TMDX.US) With Hold Rating, Cuts Target Price to $87
Morgan Stanley Sticks to Their Hold Rating for TransMedics Group (TMDX)
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $180
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $150 to $180